SMTI

Sanara Medtech Inc. (SMTI) - 10-Q Summary

Business Context and Reporting Period

Company: Sanara Medtech Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: Sanara is a medical technology company focused on soft tissue repair and bone fusion products for the surgical market. Following the discontinuation of its Tissue Health Plus (THP) segment in September 2025, the Company now operates as a single reportable segment (Sanara Surgical).
Subsequent Event: On July 29, 2026, the Company entered into a definitive merger agreement to be acquired by MiMedx Group, Inc. for $33.00 per share in cash plus 0.4735 shares of MiMedx stock.

Key Financial Metrics (Six Months Ended June 30, 2026)

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 14% year-over-year (YoY) to $55.9 million, driven by a 16% increase in soft tissue repair product sales (including CellerateRX and BIASURGE), partially offset by a 5% decline in bone fusion products.
• Profitability: The Company moved from a net loss of $5.5 million in the prior year period to a net income of $5,739. This improvement is largely due to the classification of the THP segment as discontinued operations, which previously incurred significant losses ($5.4 million in the prior period).
• Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased 15% YoY to $44.5 million, primarily due to increased sales/marketing spend ($3.1M increase) and legal/advisory fees related to strategic initiatives ($1.1M increase).
• Discontinued Operations: The THP segment was fully wound down as of December 31, 2025. Remaining costs in the current period are minimal ($41,720 loss for Q2 2026).
• Debt: The Company maintains a $42.75 million principal balance on its CRG Term Loan. Interest expense increased due to the full drawdown of the facility and the election to pay interest in cash rather than PIK (Paid-in-Kind) for the current period.

Guidance, Outlook, and Risks

• Merger Transaction: The pending merger with MiMedx is the primary strategic focus. The transaction is subject to shareholder approval, SEC registration effectiveness, and regulatory approvals (HSR Act). If consummated, Sanara will become a private subsidiary.
• Liquidity: Management believes current cash ($15.4M) and operating cash flows are sufficient to fund operations for at least the next 12 months. The Company is in compliance with all debt covenants, including minimum revenue and liquidity requirements.
• Strategic Shift: The Company has terminated non-core agreements (Tufts University license, Petito Services Agreement, Catalyst Services Agreement) to refocus exclusively on surgical products.
• Risks: Key risks include the failure to consummate the merger, potential class action litigation related to the merger, and the ability to meet future revenue covenants under the CRG Term Loan ($85M annual minimum for 2026).

Investor Verification Checklist

• Merger Approval: Verify the status of shareholder voting and regulatory clearance for the MiMedx acquisition.
• Debt Covenants: Confirm compliance with the $85 million annual minimum revenue covenant for the 2026 fiscal year under the CRG Term Loan.
• Discontinued Operations: Review Note 3 to ensure all THP-related liabilities and wind-down costs have been fully accounted for and no material contingent liabilities remain.
• Equity Method Investments: Monitor the performance of investments in BMI, ChemoMouthpiece, and SI Technologies, which contributed $0.9 million to losses in the first half of 2026.
• Termination Fees: Note the potential $9.7 million termination fee payable by Sanara if the merger is terminated to accept a superior proposal.